Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex

被引:19
|
作者
Garcia-Fernandez, Sergio [1 ,2 ,8 ]
Bala, Yohann [3 ]
Armstrong, Tom [4 ]
Garcia-Castillo, Maria [1 ,2 ,8 ]
Burnham, Carey-Ann D. [5 ]
Wallace, Meghan A. [5 ]
Hardy, Dwight [6 ]
Zambardi, Gilles [7 ]
Canton, Rafael [1 ,2 ,8 ]
机构
[1] Hosp Univ Ramon & Cajal, Serv Microbiol, Madrid, Spain
[2] IRYCIS, Madrid, Spain
[3] BioMerieux Global Clin Affairs, Marcy Letoile, France
[4] BioMerieux Global Clin Affairs, Hazelwood, MO USA
[5] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA
[6] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
[7] BioMerieux, La Balme Les Grottes, France
[8] REIPI, Madrid, Spain
关键词
piperacillin-tazobactam; Etest; antimicrobial susceptibility testing; gradient diffusion; Enterobacterales; Pseudomonas aeruginosa; Acinetobacter baumannii complex; ESCHERICHIA-COLI; LACTAMASE;
D O I
10.1128/JCM.01042-19
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Piperacillin-tazobactam (P/T) is a beta-lactam-beta-lactamase inhibitor combination frequently used in the hospital setting. Etest is a gradient diffusion method that represents an alternative to broth microdilution (BMD) for performing antimicrobial susceptibility testing. We conducted a multicenter evaluation of the performance of the new P/T Etest compared to that of BMD following U.S. Food and Drug Administration (FDA) and International Standards Organization (ISO) standard ISO 20776-2 criteria using Clinical and Laboratory Standards Institute (CLSI)-FDA and European Committee on Antimicrobial Susceptibility Testing (EUCAST) interpretive breakpoints, respectively. A total of 977 isolates (775 Enterobacterales isolates, 119 Pseudomonas aeruginosa isolates, and 83 Acinetobacter baumannii complex isolates) were tested. Overall essential agreement (EA) was 96.4% and 96.6% for Enterobacterales when FDA and ISO 20776-2 criteria, respectively, were followed. EA was 98.3% for P. aeruginosa and 91.6% for the A. baumannii complex when both the FDA and ISO criteria were followed. Applying CLSI-FDA breakpoints, categorical agreement (CA) reached 93.0%, 93.3%, and 89.2% for the Enterobacterales, P. aeruginosa, and the A. baumannii complex, respectively. Two very major errors (VMEs; 1.1%) were found among the Enterobacterales (for 2 Klebsiella pneumoniae isolates). No additional major errors (MEs) or VMEs were found. Applying EUCAST breakpoints, CA was 94.8% and 95.8% for Enterobacterales and P. aeruginosa, respectively (no breakpoints are currently available for the A. baumannii complex). No VMEs were observed among the Enterobacterales, but 2 (0.4%) MEs were found. Among the P. aeruginosa isolates, 2 (6.9%) VMEs and 3 (33%) MEs were observed. These errors resulted when P/T Etest MICs were 1 doubling dilution apart from the BMD MICs. In conclusion, the new P/T Etest represents an accurate tool for performing antimicrobial susceptibility testing of Enterobacterales, P. aeruginosa, and A. baumannii complex isolates with limited category errors.
引用
收藏
页数:9
相关论文
共 25 条
  • [21] Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020
    Jean, Shio-Shin
    Ko, Wen-Chien
    Lu, Min-Chi
    Lee, Wen-Sen
    Hsueh, Po-Ren
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (06) : 941 - 953
  • [22] Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains
    Lo-Ten-Foe, Jerome R.
    de Smet, Anne Marie G. A.
    Diederen, Bram M. W.
    Kluytmans, Jan A. J. W.
    van Keulen, Peter H. J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (10) : 3726 - 3730
  • [23] Evaluation of imipenem-relebactam susceptibility testing in carbapenem resistant Pseudomonas aeruginosa: comparison of sensititre microplates, disc diffusion, and MTS gradient strips with broth microdilution
    Biguenet, Adrien
    Devoos, Lea
    Rousselot, Julie
    Bour, Maxime
    Fournier, Damien
    Jeannot, Katy
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2025,
  • [24] Carbapenem Susceptibility Testing Errors Using Three Automated Systems, Disk Diffusion, Etest, and Broth Microdilution and Carbapenem Resistance Genes in Isolates of Acinetobacter baumannii-calcoaceticus Complex (vol 55, pg 4707, 2011)
    Markelz, Ana Elizabeth
    Mende, Katrin
    Murray, Clinton K.
    Yu, Xin
    Zera, Wendy C.
    Hospenthal, Duane R.
    Beckius, Miriam L.
    Calvano, Tatjana
    Akers, Kevin S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (02) : 1149 - 1149
  • [25] Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin
    Espinel-Ingroff, A.
    Arthington-Skaggs, B.
    Iqbal, N.
    Ellis, D.
    Pfaller, M. A.
    Messer, S.
    Rinaldi, M.
    Fothergill, A.
    Gibbs, D. L.
    Wang, A.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (06) : 1811 - 1820